Skip to main content

Table 1 S1 Studies in Advanced Gastric Cancer

From: Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Abstract/author Study agents Patient number Study Design RR PFS OS
A4534/
Jeung et al.
S1, Docetaxel, Cisplatin 80 Randomized phase II Docetaxel + S1 or Docetaxel + cisplatin 44%
24%
198 days
143 days
(p = 0.03)
NR
A4533/
Jin et al.
S1
Cisplatin
5-FU
230 Randomized phase III S1 vs. S1 + cisplatin vs. 5-FU + cisplatin 25%
38%
19%
(p = 0.021)
267 days
433 days
309 days
(p = 0.008)
NR
A4537/
Sato et al.
S1
Docetaxel
Cisplatin
31 Phase II study 87% 7.7 months 19 months
  1. RR: Response rate; PFS: Progression-free survival; OS: Overall survival; NR: Not reported.